— Why it moved
Why IRD Stock Spiked and Faded Today — September 9, 2026
Opus Genetics popped on early trial data and analyst target upgrades, but buying pressure vanished right after the morning rush.
What moved IRD stock
Opus Genetics is a clinical-stage biotech developing gene therapies for inherited eye diseases. They released Phase 1/2 trial data showing visual improvements in retinal disease patients alongside FDA alignment for pivotal trials. Wall Street analysts rushed to double price targets, fueling an early rush of retail interest.
The mechanics
The stock gapped up over 22% at the session's start on a 65 million share float. High churning produced 54 million shares in volume, but existing holders used the liquidity boost to sell directly into the morning spike.
IRD by the numbers
The alert window
This signal was a complete dud. The alert triggered at 6.92 at 9:48 AM, which happened to be the high minute of the day as price topped at 7.07. Anyone following the alert had four total minutes above the signal price before the stock dumped.
How IRD's move ended
Shares dropped continuously through the afternoon to close at 5.72, down 17.3% from the alert price. Early trial headlines often fail to sustain intraday momentum without actual revenue on the horizon.
The tell: Chasing a biotech breakout nearly an hour into the session usually means you are providing liquidity for early buyers.